This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Castelli-Haley J, Lage MJ, Oleen-Burkey M.A comparison of outcomes among multiple sclerosis patients treated with glatiramer acetate injection or high-dose interferon beta-1A. Value in Health 10: A387 (plus poster) abstr. PND23, No. 6, Nov-Dec 2007
Teva Pharmaceutical Industries Ltd.New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE (Rm) is More Cost Effective Than Tysabri (Rm) for Treatment of Relapsing-Remitting Multiple Sclerosis. Media Release: 26 Oct 2007. Available from: URL: http://www.tevapharm.com
Rights and permissions
About this article
Cite this article
Glatiramer acetate triumphs in MS. Pharmacoecon. Outcomes News 541, 6 (2007). https://doi.org/10.2165/00151234-200705410-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705410-00008